Invacare offers to buy Healthdyne
This article was originally published in Clinica
Executive Summary
Invacare wants to take over Healthdyne Technologies and is offering $12.50 a share in cash, valuing Healthdyne at some $158 million. The price offered by Invacare represents a premium of 40% over the share price on December 31st, 1996. Healthdyne says it will not consider the offer until its board meeting in February. The share price before the offer was made public was $9.25 and reached $13.25 by the close of January 13th.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.